The antimicrobials segment is the market leader. This dominance is driven by the critical role antimicrobials play in controlling bacterial infections across various animal species, with classical APIs like penicillins and tetracyclines remaining highly popular, particularly in developing regions.
The vaccines segment is registering the fastest growth. This surge is attributed to increasing global outbreaks of viral diseases in poultry and swine, leading to higher demand for API components such as viral antigens and adjuvants for pandemic preparedness and routine immunization.
Key drivers include the rising global livestock population to meet food safety needs, increased pet ownership in urban areas, the threat of zoonotic diseases (such as avian influenza and African swine fever), and technological advancements in precision medicine and long-acting injectables.
North America is the current market leader due to its advanced R&D ecosystem and stringent regulatory frameworks. However, the Asia-Pacific region is expected to experience the highest CAGR through 2035, driven by heavy investments in livestock productivity and the presence of large-scale, low-cost production units in India and China.
Regulatory bodies like the FDA and EMA have tightened controls on the indiscriminate use of antibiotics in food animals. This has pushed manufacturers to shift away from broad-spectrum antibiotics toward developing narrow-spectrum, targeted APIs and precision drugs that offer residue-free compliance.
Manufacturers face several hurdles, including the rising threat of antibiotic resistance, complex and varying regulatory requirements across different regions, high costs associated with maintaining GMP-certified facilities, and quality consistency risks associated with outsourcing production to cost-effective hubs.
Sustainability-driven API synthesis is a major emerging trend. Manufacturers are increasingly adopting green chemistry and environmentally sustainable synthesis methods to meet evolving environmental regulations and reduce the ecological footprint of pharmaceutical production, particularly in Europe.
In 2024, Zoetis Inc. announced multimillion-dollar investments in R&D hubs in Europe and North America. Elanco Animal Health acquired a specialized biological API manufacturer to boost vertical integration, and new APIs have been launched specifically for treating osteoarthritis in companion animals with fewer side effects.
Significant opportunities include the expansion of vaccine API procurement for government-backed disease eradication programs, the development of low-dose and high-efficiency APIs for personalized treatment, and the growth of Contract Development and Manufacturing Organizations (CDMOs) that offer flexible scalability for specialized veterinary APIs.
